Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis

Biochemistry Research International

Volumn , Issue , 2012, Pages

  Mohanan, Sunish ^a   Cherrington, Brian D ^b   Horibata, Sachi ^a   McElwee, John L ^a   Thompson, Paul R ^c   Coonrod, Scott A ^a  

^a Department of Molecular Biology and Genetics   (United States)

^b UNIVERSITY OF WYOMING   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867386515     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2012/895343     Document Type: Review

References (81)

1. Vossenaar E. R., Zendman A. J. W., Van Venrooij W. J., Pruijn G. J. M., PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 2003 25 11 1106 1118 2-s2.0-0242720407 10.1002/bies.10357
2. Denman R. B., PAD: the smoking gun behind arginine methylation signaling? BioEssays 2005 27 3 242 246 2-s2.0-15944368623 10.1002/bies.20205
3. Anzilotti C., Pratesi F., Tommasi C., Migliorini P., Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmunity Reviews 2010 9 3 158 160 2-s2.0-72149084899 10.1016/j.autrev.2009.06.002
4. Chang X., Yamada R., Suzuki A., Sawada T., Yoshino S., Tokuhiro S., Yamamoto K., Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology 2005 44 1 40 50 2-s2.0-12344327644 10.1093/rheumatology/keh414
5. Chang X., Han J., Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Molecular Carcinogenesis 2006 45 3 183 196 2-s2.0-33644830015 10.1002/mc.20169
6. Jones J. E., Causey C. P., Knuckley B., Slack-Noyes J. L., Thompson P. R., Protein arginine deiminase 4 (PAD4): current understanding and future therapeutic potential. Current Opinion in Drug Discovery and Development 2009 12 5 616 627 2-s2.0-70149086262
7. De Ceuleneer M., Van Steendam K., Dhaenens M., Deforce D., In vivo relevance of citrullinated proteins and the challenges in their detection. Proteomics 2012 12 752 760 10.1002/pmic.201100478
8. Chavanas S., Méchin M. C., Takahara H., Kawada A., Nachat R., Serre G., Simon M., Comparative analysis of the mouse and human peptidylarginine deiminase gene clusters reveals highly conserved non-coding segments and a new human gene, PADI6. Gene 2004 330 1-2 19 27 2-s2.0-1842829046 10.1016/j.gene.2003.12.038
9. Vossenaar E. R., Nijenhuis S., Helsen M. M. A., Van der Heijden A., Senshu T., Van den Berg W. B., Van Venrooij W. J., Joosten L. A. B., Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis and Rheumatism 2003 48 9 2489 2500 2-s2.0-0141564989 10.1002/art.11229
10. Ellsworth R. E., Vertrees A., Love B., Hooke J. A., Ellsworth D. L., Shriver C. D., Cronin K., Chromosomal alterations associated with the transition from in situ to invasive breast cancer. Annals of Surgical Oncology 2008 15 9 2519 2525 2-s2.0-50049097725 10.1245/s10434-008-0051-7
11. Darrah E., Rosen A., Giles J. T., Andrade F., Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Annals of the Rheumatic Diseases 2012 71 92 98 10.1136/ard.2011.151712
12. Knuckley B., Causey C. P., Jones J. E., Bhatia M., Dreyton C. J., Osborne T. C., Takahara H., Thompson P. R., Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry 2010 49 23 4852 4863 2-s2.0-77953258110 10.1021/bi100363t
13. Pritzker L. B., Joshi S., Harauz G., Moscarello M. A., Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase. Biochemistry 2000 39 18 5382 5388 2-s2.0-0034625146 10.1021/bi9925571
14. Pritzker L. B., Joshi S., Gowan J. J., Harauz G., Moscarello M. A., Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000 39 18 5374 5381 2-s2.0-0034625091 10.1021/bi9925569
15. Musse A. A., Zhen L., Ackerley C. A., Bienzle D., Lei H., Poma R., Harauz G., Moscarello M. A., Mastronardi F. G., Peptidylarginine deiminase 2 (PAD2) overexpression in transgenic mice leads to myelin loss in the central nervous system. Disease Models and Mechanisms 2008 1 4-5 229 240 2-s2.0-64249156653 10.1242/dmm.000729
16. Vossenaar E. R., Radstake T. R. D., Van Der Heijden A., Van Mansum M. A. M., Dieteren C., De Rooij D. J., Barrera P., Zendman A. J. W., Van Venrooij W. J., Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Annals of the Rheumatic Diseases 2004 63 4 373 381 2-s2.0-1842453329 10.1136/ard.2003.012211
17. Cherrington B. D., Morency E., Struble A. M., Coonrod S. A., Wakshlag J. J., Potential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones. PLoS ONE 2010 5 7 2-s2.0-77955651633 10.1371/journal.pone.0011768 e11768
18. Cherrington B. D., Zhang X., McElwee J. L., Morency E., Anguish L. J., Coonrod S. A., Potential role for PAD2 in gene regulation in breast cancer cells. PloS ONE 2012 7 e41242
19. Zhang X., Bolt M., Guertin M. J., Chen W., Zhang S., Cherrington B. D., Slade D. J., Dreyton C. J., Subramanian V., Bickere K. L., Thompson P. L., Mancini M. A., Lis J. T., Coonrod S. A., Peptidylarginine deiminase 2-catalyzed histone H3 arginine 26 citrullination facilitates estrogen receptor α target gene activation. Proceedings of the National Academy of Sciences of the United States of America 2012 109 33 13331 13336 10.1073/pnas.1203280109
20. Nachat R., Méchin M. C., Takahara H., Chavanas S., Charveron M., Serre G., Simon M., Peptidylarginine deiminase isoforms 13 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. Journal of Investigative Dermatology 2005 124 2 384 393 2-s2.0-12944329841 10.1111/j.0022-202X.2004.23568.x
21. Chang X., Fang K., PADI4 and tumourigenesis. Cancer Cell International 2010 10, article 7 2-s2.0-79959508911 10.1186/1475-2867-10-7
22. Nakashima K., Hagiwara T., Yamada M., Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes. Journal of Biological Chemistry 2002 277 51 49562 49568 2-s2.0-0037147140 10.1074/jbc.M208795200
23. Chang X., Yamada R., Sawada T., Suzuki A., Kochi Y., Yamamoto K., The inhibition of antithrombin by peptidylarginine deiminase 4 may contribute to pathogenesis of rheumatoid arthritis. Rheumatology 2005 44 3 293 298 2-s2.0-14944379544 10.1093/rheumatology/keh473
24. Ordóñez A., Martínez-Martínez I., Corrales F. J., Miqueo C., Miñano A., Vicente V., Corral J., Effect of citrullination on the function and conformation of antithrombin. The FEBS Journal 2009 276 22 6763 6772 2-s2.0-70350435268 10.1111/j.1742-4658.2009.07391.x
25. Ordóñez A., Yélamos J., Pedersen S., Miñano A., Conesa-Zamora P., Kristensen S. R., Stender M. T., Thorlacius-Ussing O., Martínez-Martínez I., Vicente V., Corral J., Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thrombosis and Haemostasis 2010 104 6 1143 1149 2-s2.0-78649719869 10.1160/TH10-05-0297
26. Tanikawa C., Ueda K., Nakagawa H., Yoshida N., Nakamura Y., Matsuda K., Regulation of protein citrullination through p53/PADI4 Network in DNA damage response. Cancer Research 2009 69 22 8761 8769 2-s2.0-72249096427 10.1158/0008-5472.CAN-09-2280
27. Guo Q., Fast W., Citrullination of Inhibitor of Growth 4 (ING4) by Peptidylarginine Deminase 4 (PAD4) disrupts the interaction between ING4 and p53. Journal of Biological Chemistry 2011 286 19 17069 17078 2-s2.0-79955765048 10.1074/jbc.M111.230961
28. Yao H., Li P., Venters B. J., Zheng S., Thompson P. R., Pugh B. F., Wang Y., Histone Arg modifications and p53 regulate the expression of OKL38, a mediator of apoptosis. Journal of Biological Chemistry 2008 283 29 20060 20068 2-s2.0-49749112990 10.1074/jbc.M802940200
29. Li P., Yao H., Zhang Z., Li M., Luo Y., Thompson P. R., Gilmour D. S., Wang Y., Regulation of p53 target gene expression by peptidylarginine deiminase 4. Molecular and Cellular Biology 2008 28 15 4745 4758 2-s2.0-47949123469 10.1128/MCB.01747-07
30. Zhang X., Gamble M. J., Stadler S., Cherrington B. D., Causey C. P., Thompson P. R., Roberson M. S., Kraus W. L., Coonrod S. A., Genome-Wide analysis reveals PADI4 cooperates with Elk-1 to activate C-Fos expression in breast cancer cells. PLoS Genetics 2011 7 6 2-s2.0-79959821077 10.1371/journal.pgen. 1002112 e1002112
31. Wang Y., Li M., Stadler S., Correll S., Li P., Wang D., Hayama R., Leonelli L., Han H., Grigoryev S. A., Allis C. D., Coonrod S. A., Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. Journal of Cell Biology 2009 184 2 205 213 2-s2.0-60849099332 10.1083/jcb.200806072
32. Tanikawa C., Espinosa M., Suzuki A., Masuda K., Yamamoto K., Tsuchiya E., Ueda K., Daigo Y., Nakamura Y., Matsuda K., Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. Nature Communications 2012 3, article 676 10.1038/ncomms1676
33. Rust H. L., Thompson P. R., Kinase consensus sequences: a breeding ground for crosstalk. ACS Chemical Biology 2011 6 881 892 10.1021/cb200171d
34. Li P., Wang D., Yao H., Doret P., Hao G., Shen Q., Qiu H., Zhang X., Wang Y., Chen G., Wang Y., Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 2010 29 21 3153 3162 2-s2.0-77952954497 10.1038/onc.2010.51
35. Yurttas P., Vitale A. M., Fitzhenry R. J., Cohen-Gould L., Wu W., Gossen J. A., Coonrod S. A., Role for PADI6 and the cytoplasmic lattices in ribosomal storage in oocytes and translational control in the early mouse embryo. Development 2008 135 15 2627 2636 2-s2.0-50649095772 10.1242/dev.016329
36. Stacey S. N., Gudbjartsson D. F., Sulem P., Bergthorsson J. T., Kumar R., Thorleifsson G., Sigurdsson A., Jakobsdottir M., Sigurgeirsson B., Benediktsdottir K. R., Thorisdottir K., Ragnarsson R., Scherer D., Rudnai P., Gurzau E., Koppova K., Höiom V., Botella-Estrada R., Soriano V., Juberías P., Grasa M., Carapeto F. J., Tabuenca P., Gilaberte Y., Gudmundsson J., Thorlacius S., Helgason A., Thorlacius T., Jonasdottir A., Blondal T., Gudjonsson S. A., Jonsson G. F., Saemundsdottir J., Kristjansson K., Bjornsdottir G., Sveinsdottir S. G., Mouy M., Geller F., Nagore E., Mayordomo J. I., Hansson J., Rafnar T., Kong A., Olafsson J. H., Thorsteinsdottir U., Stefansson K., Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nature Genetics 2008 40 11 1313 1318 2-s2.0-55049127580 10.1038/ng.234
37. Yurttas P., Morency E., Coonrod S. A., Use of proteomics to identify highly abundant maternal factors that drive the egg-to-embryo transition. Reproduction 2010 139 5 809 823 2-s2.0-77951609161 10.1530/REP-09-0538
38. Li L., Zheng P., Dean J., Maternal control of early mouse development. Development 2010 137 6 859 870 2-s2.0-77950347539 10.1242/dev.039487
39. Senshu T., Akiyama K., Nagata S., Watanabe K., Hikichi K., Peptidylarginine deiminase in rat pituitary: sex difference, estrous cycle-related changes, and estrogen dependence. Endocrinology 1989 124 6 2666 2670 2-s2.0-0024384763
40. Takahara H., Tsuchida M., Kusubata M., Akutsu K., Tagami Sugawara S. K., Peptidylarginine deiminase of the mouse. Distribution, properties, and immunocytochemical localization. Journal of Biological Chemistry 1989 264 22 13361 13368 2-s2.0-0024368848
41. Watanabe K., Nomoto M., Nagata S., Itoh Y., Hikichi K., Maruyama N., Mita T., Senshu T., The rat peptidylarginine deiminase-encoding gene: structural analysis and the 5'-flanking sequence. Gene 1992 114 2 261 265 2-s2.0-0026633309 10.1016/0378-1119(92)90585-D
42. Nagata S., Uehara T., Inoue K., Senshu T., Increased peptidylarginine deiminase expression during induction of prolactin biosynthesis in a growth-hormone-producing rat pituitary cell line, MtT/S. Journal of Cellular Physiology 1992 150 2 426 432 2-s2.0-0026514063
43. Barrett T., Troup D. B., Wilhite S. E., Ledoux P., Rudnev D., Evangelista C., Kim I. F., Soboleva A., Tomashevsky M., Marshall K. A., Phillippy K. H., Sherman P. M., Muertter R. N., Edgar R., NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Research 2009 37 1 D885 D890 2-s2.0-58149182724 10.1093/nar/gkn764
44. Hewitt S. C., Deroo B. J., Hansen K., Collins J., Grissom S., Afshari C. A., Korach K. S., Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Molecular Endocrinology 2003 17 10 2070 2083 2-s2.0-0142056951 10.1210/me.2003-0146
45. Takahara H., Kusubata M., Tsuchida M., Kohsaka T., Tagami S., Sugawara K., Expression of peptidylarginine deiminase in the uterine epithelial cells of mouse is dependent on estrogen. Journal of Biological Chemistry 1992 267 1 520 525 2-s2.0-0026543521
46. Horibata S., Coonrod S. A., Cherrington B. D., Role for peptidylarginine deiminase enzymes in disease and female reproduction. The Journal of Reproduction and Development 2012 58 274 282 10.1262/jrd.2011-040
47. Dong S., Zhang Z., Takahara H., Estrogen-enhanced peptidylarginine deiminase type IV gene (PADI4) expression in MCF-7 cells is mediated by estrogen receptor- α -promoted transfactors activator protein-1, nuclear factor-Y, and Sp1. Molecular Endocrinology 2007 21 7 1617 1629 2-s2.0-34347241381 10.1210/me.2006-0550
48. Wang Y., Wysocka J., Sayegh J., Lee Y. H., Pertin J. R., Leonelli L., Sonbuchner L. S., McDonald C. H., Cook R. G., Dou Y., Roeder R. G., Clarke S., Stallcup M. R., Allis C. D., Coonrod S. A., Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004 306 5694 279 283 2-s2.0-5044228483 10.1126/science.1101400
49. Chumanevich A. A., Causey C. P., Knuckley B. A., Jones J. E., Poudyal D., Chumanevich A. P., Davis T., Matesic L. E., Thompson P. R., Hofseth L. J., Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. American Journal of Physiology 2011 300 6 G929 G938 2-s2.0-79957951714 10.1152/ajpgi.00435.2010
50. Tait L. R., Pauley R. J., Santner S. J., Heppner G. H., Heng H. H., Rak J. W., Miller F. R., Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. International Journal of Cancer 2007 120 10 2127 2134 2-s2.0-34147136520 10.1002/ijc.22572
51. Miller F. R., Santner S. J., Tait L., Dawson P. J., MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. Journal of the National Cancer Institute 2000 92 14 1185 1186 2-s2.0-0034686626
52. Wang L., Chang X., Yuan G., Zhao Y., Wang P., Expression of peptidylarginine deiminase type 4 in ovarian tumors. International Journal of Biological Sciences 2010 6 5 454 464 2-s2.0-77957136397
53. Chang X., Han J., Pang L., Zhao Y., Yang Y., Shen Z., Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 2009 9, article 40 2-s2.0-60549084383 10.1186/1471-2407-9-40
54. Cherrington B. D., Mohanan S., Diep A. N., Fleiss R., Sudilovsky D., Anguish L. J., Coonrod S. A., Wakshlag J. J., Comparative analysis of peptidylarginine deiminase-2 expression in canine, feline and human mammary tumours. Journal of Comparative Pathology 2012 147 139 146 10.1016/j.jcpa.2012. 01.021
55. Slack J. L., Causey C. P., Thompson P. R., Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cellular and Molecular Life Sciences 2011 68 4 709 720 2-s2.0-79951578893 10.1007/s00018-010-0480-x
56. Luo Y., Arita K., Bhatia M., Knuckley B., Lee Y. H., Stallcup M. R., Sato M., Thompson P. R., Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 2006 45 39 11727 11736 2-s2.0-33749359452 10.1021/bi061180d
57. Luo Y., Knuckley B., Lee Y. H., Stallcup M. R., Thompson P. R., A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. Journal of the American Chemical Society 2006 128 4 1092 1093 2-s2.0-31944448153 10.1021/ja0576233
58. Knuckley B., Luo Y., Thompson P. R., Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorganic and Medicinal Chemistry 2008 16 2 739 745 2-s2.0-38549168544 10.1016/j.bmc.2007.10.021
59. Wang Y., Li P., Wang S., Hu J., Chen X. A., Wu J., Fisher M., Oshaben K., Zhao N., Gu Y., Wang D., Chen G., Wang Y., Anticancer PAD inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. The Journal of Biological Chemistry 2012 287 25941 25953 10.1074/jbc.M112.375725
60. Van C. W., Alison M. G., Nirmal K. B., Corey P. C., Bryan Knuckley, Kristen N. C., Yuan Luo, Brandt Levitt, Magdalena Glogowska, Piyanka Chandra, Liudmila Kulik, William H. R., William P. A., Thompson P. R., Holers V. M., N- α -benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. Journal of Immunology 2011 186 7 4396 4404 2-s2.0-79955006474 10.4049/jimmunol.1001620
61. Pierce B. L., Neuhouser M. L., Wener M. H., Bernstein L., Baumgartner R. N., Ballard-Barbash R., Gilliland F. D., Baumgartner K. B., Sorensen B., McTiernan A., Ulrich C. M., Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Research and Treatment 2009 114 1 155 167 2-s2.0-58849085141 10.1007/s10549-008-9985-5
62. Ahmed O. I., Adel A. M., Diab D. R., Gobran N. S., Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. The Egyptian Journal of Immunology 2006 13 2 61 68 2-s2.0-52149115150
63. Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J. Y., Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British Journal of Cancer 2003 88 11 1721 1726 2-s2.0-0037591513 10.1038/sj.bjc.6600956
64. Cole S. W., Chronic inflammation and breast cancer recurrence. Journal of Clinical Oncology 2009 27 21 3418 3419 2-s2.0-70249113748 10.1200/JCO.2009.21. 9782
65. Salgado R., Junius S., Benoy I., Van Dam P., Vermeulen P., Van Marck E., Huget P., Dirix L. Y., Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International Journal of Cancer 2003 103 5 642 646 2-s2.0-0037455841 10.1002/ijc.10833
66. Zhang G. J., Adachi I., Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Research 1999 19 2 1427 1432 2-s2.0-0033036097
67. Coussens L. M., Werb Z., Inflammation and cancer. Nature 2002 420 6917 860 867 2-s2.0-0037180757 10.1038/nature01322
68. Fidler I. J., The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer 2003 3 6 453 458 2-s2.0-0038481970 10.1038/nrc1098
69. Auger I., Charpin C., Balandraud N., Martin M., Roudier J., Autoantibodies to PAD4 and BRAF in rheumatoid arthritis. Autoimmunity Reviews 2012 11 11 801 803 10.1016/j.autrev.2012.02.009
70. Saffarzadeh M., Juenemann C., Queisser M. A., Lochnit G., Barreto G., Galuska S. P., Lohmeyer J., Preissner K. T., Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PloS ONE 2012 7 e32366
71. Liu C. L., Tangsombatvisit S., Rosenberg J. M., Mandelbaum G., Gillespie E. C., Gozani O. P., Alizadeh A. A., Utz P. J., Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Research & Therapy 2012 14, article R25
72. Amulic B., Hayes G., Neutrophil extracellular traps. Current Biology 2011 21 9 R297 R298 2-s2.0-79955647642 10.1016/j.cub.2011.03.021
73. Li P., Li M., Lindberg M. R., Kennett M. J., Xiong N., Wang Y., PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. Journal of Experimental Medicine 2010 207 9 1853 1862 2-s2.0-77956245423 10.1084/jem.20100239
74. Fan L., He D., Wang Q., Zong M., Zhang H., Yang L., Sun L., Citrullinated vimentin stimulates proliferation, pro-inflammatory cytokine secretion, and PADI4 and RANKL expression of fibroblast-like synoviocytes in rheumatoid arthritis. Scandinavian Journal of Rheumatology. In press
75. Lee H. J., Joo M., Abdolrasulnia R., Young D. G., Choi I., Ware L. B., Blackwell T. S., Christman B. W., Peptidylarginine deiminase 2 suppresses inhibitory κ B kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages. Journal of Biological Chemistry 2010 285 51 39655 39662 2-s2.0-78650051608 10.1074/jbc.M110.170290
76. Ruiz-Esquide V., Gomara M. J., Peinado V. I., Puerta J. A., Barbera J. A., de Dios Canete J., Haro I., Sanmarti R., Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease? Clinical Rheumatology 2012 31 1047 1050 10.1007/s10067-012-1971-y
77. Kilsgard O., Andersson P., Malmsten M., Nordin S. L., Linge H. M., Eliasson M., Sorenson E., Erjefalt J. S., Bylund J., Olin A. I., Sorensen O. E., Egesten A., Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities. American Journal of Respiratory Cell and Molecular Biology 2012 46 240 248 10.1165/rcmb.2010-0500OC
78. Makrygiannakis D., Af Klint E., Lundberg I. E., Löfberg R., Ulfgren A. K., Klareskog L., Catrina A. I., Citrullination is an inflammation-dependent process. Annals of the Rheumatic Diseases 2006 65 9 1219 1222 2-s2.0-33747805326 10.1136/ard.2005.049403
79. Coudane F., Mechin M. C., Huchenq A., Henry J., Nachat R., Ishigami A., Adoue V., Sebbag M., Serre G., Simon M., Deimination and expression of peptidylarginine deiminases during cutaneous wound healing in mice. European Journal of Dermatology 2011 21 3 376 384 2-s2.0-79960823772 10.1684/ejd.2011. 1394
80. Mortier A., Gouwy M., Van Damme J., Proost P., Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Experimental Cell Research 2011 317 5 642 654 2-s2.0-79952102426 10.1016/j.yexcr.2010.11.016
81. Proost P., Loos T., Mortier A., Schutyser E., Gouwy M., Noppen S., Dillen C., Ronsse I., Conings R., Struyf S., Opdenakker G., Maudgal P. C., Van Damme J., Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. Journal of Experimental Medicine 2008 205 9 2085 2097 2-s2.0-51049113366 10.1084/jem.20080305